From Neutral to Strategic: Why Sentiment Doesn't Drive AI Performance in Pharma

The brand with the most positive AI sentiment scores 21 points below the leader. Here's why.

If you work in pharmaceutical marketing, you have been trained to believe that positive brand perception is the ultimate metric. Higher favorability drives prescribing behavior, patient preference, and market share. It is the foundational logic behind every brand campaign, every KOL engagement, and every patient education initiative.

So when pharma teams first encounter Generative Engine Optimization (GEO) data, their instinct is predictable: chase positive sentiment in AI responses. Make ChatGPT say nice things about the brand. Get Gemini to frame the drug favorably. Ensure Perplexity positions the product as a first-line choice.

The data says this instinct is wrong.

Across 23 pharmaceutical brands and three major AI models, we found no meaningful correlation between pharma AI sentiment and overall GEO performance. The most positively framed brand in our dataset scores in the bottom third. A brand with zero sentiment scores in the top five. And the highest-performing brand of all sits at a modest, unremarkable 50/100 on sentiment.

The metric that actually predicts GEO performance? Reliability. Not how positively AI models talk about your drug --- but how accurately.

Key Takeaway: Positive sentiment does not drive AI performance in pharma. Across 23 brands, reliability (factual accuracy against approved labeling) is the only consistent predictor of overall GEO score. Brands chasing favorable AI framing are optimizing the wrong variable.

Data source: PharmaGEO platform analysis of 23 pharmaceutical brands across OpenAI, Gemini, and Perplexity (2025)

---

The Myth: Positive Sentiment = Better AI Performance

The assumption is understandable. In traditional marketing, brand sentiment is a leading indicator. Positive perception in surveys, social listening, and media analysis correlates with market performance. Brands invest heavily in shaping how they are perceived because perception drives behavior.

Pharma teams naturally extend this logic to AI. If a patient asks ChatGPT about a drug, a positive framing should theoretically drive more confidence, more adherence, more prescriptions. If a physician queries Perplexity for a treatment comparison, a favorably positioned brand should win the recommendation.

This reasoning has three flaws:

1. AI models are not audiences. They do not respond to persuasion the way patients or physicians do. Positive framing does not make a model more likely to recommend a drug.

2. AI models penalize promotional language. Content that reads as marketing triggers lower reliability assessments, which reduce overall performance --- the opposite of the intended effect.

3. The regulatory environment forces neutrality. AI models are trained on clinical literature, prescribing information, and regulatory documents that are inherently neutral. The training data itself establishes neutral as the default.

Yet the myth persists. Brand teams still ask: How do we make AI sentiment more positive? The better question is: Why is sentiment the wrong metric entirely?

Related: Benchmarking Pharma GEO: What 23 Brands Reveal

---

The Data: Pharma AI Sentiment vs. GEO Score

Here is the complete sentiment-score comparison for the brands where the disconnect is most visible. Study it carefully. The non-correlation is the finding.

What This Table Reveals

Parodontax is the most positively framed pharmaceutical brand in our entire dataset, with a sentiment score of 80/100. AI models describe it in overtly favorable terms. Yet its overall GEO score is just 45 --- a full 21 points below Beyfortus, the dataset leader. Positive sentiment did not translate into performance. It was irrelevant to it.

Braftovi sits at the opposite extreme. Its sentiment score is literally zero --- AI models describe it in completely neutral, clinical terms. No positive framing whatsoever. And yet Braftovi scores 60, placing it among the top performers in the entire benchmark. Zero sentiment. Strong performance.

Ledaga demonstrates the same disconnect from the negative side. With a sentiment of -10/100, it is the most negatively framed brand in this subset. Its GEO score? 49 --- higher than Parodontax, which has 90 sentiment points more. Higher than Wegovy. Higher than Voltaren.

If sentiment drove GEO performance, the rank order of this table would be perfectly correlated. Parodontax would lead. Ledaga would trail. The data shows no such pattern.

Key Takeaway: The brand with the highest pharma AI sentiment (Parodontax, 80/100) scores 21 points below the brand with moderate sentiment (Beyfortus, 50/100). Sentiment and GEO score move independently.

---

What Actually Drives GEO Performance: Reliability, Not Sentiment

If sentiment does not predict GEO score, what does? The answer is consistent and unambiguous across the full 23-brand dataset: reliability.

Reliability measures how accurately AI models represent a drug against its approved labeling --- indications, dosing, contraindications, mechanism of action. It is a factual accuracy metric, not a perception metric. And it is the single strongest predictor of where a brand lands in the GEO scorecard.

The Reliability-Score Correlation

The pattern is clear. Brands with reliability above 80% consistently score above 50 on overall GEO performance. Brands with reliability below 75% cluster in the low-to-mid 40s. The correlation is not perfect --- other factors like citation frequency and AI visibility contribute --- but reliability is the dominant driver.

Now compare this to the sentiment data:

- Parodontax: 80/100 sentiment, 72% reliability, score 45

- Braftovi: 0/100 sentiment, 83% reliability, score 60

Parodontax has infinitely more positive sentiment. Braftovi has 11 percentage points more reliability. Braftovi wins by 15 points. Reliability overrides sentiment every single time in this dataset.

The Serelys Meno Anomaly

Serelys Meno is the most instructive case in the entire benchmark. It has a high sentiment score (65/100) and a respectable overall GEO score (61). On the surface, this looks like a sentiment success story.

Look closer: its reliability is just 48% --- the lowest in the full dataset. Serelys Meno scores well despite catastrophically low reliability because of other compensating factors in the French-language market. But that 48% reliability is a structural vulnerability. Any brand built on high sentiment and low reliability is one model update away from collapse.

Key Takeaway: Brands with reliability above 80% score 50--66 on GEO performance. Brands below 75% cluster at 43--46. Reliability is the driver. Sentiment is noise.

Related: The Reliability Tax: Why Your Own Website Is Your Biggest GEO Weakness

---

Why AI Models Default to Neutral: The Structural Explanation

The sentiment non-correlation is not a fluke. It is a structural feature of how AI models handle pharmaceutical content. Understanding why requires examining four reinforcing dynamics.

1. Medical Training Data Is Inherently Neutral

AI models learn pharmaceutical information from clinical trial publications, prescribing information documents, regulatory submissions, and medical textbooks. None of these sources use promotional language. A pivotal trial reports efficacy as a hazard ratio with confidence intervals, not as a brand success story. An FDA label describes indications, dosing, and adverse events in standardized, neutral language.

When models generate pharmaceutical content, they reproduce the register of their training data. Neutral is not a choice the model makes. It is the default established by the evidence base.

2. Positive Framing Triggers Reliability Penalties

This is the critical mechanism pharma teams miss. When content about a drug uses overtly positive language --- "breakthrough therapy," "game-changing treatment," "superior efficacy" --- AI models classify it closer to marketing material than clinical evidence. Marketing-adjacent content receives lower reliability assessments.

The result is paradoxical: the more positively you frame a drug in source content, the less reliable AI models judge that content to be. This is why Parodontax, with its strong positive sentiment, carries just 72% reliability while Braftovi, with zero sentiment, reaches 83%.

3. Regulatory Language Sets the Baseline

Every drug in our dataset has its core information encoded in regulatory documents --- FDA prescribing information, EMA summaries of product characteristics, ANSM documentation for French products. These documents follow strict formatting and language conventions. AI models treat regulatory language as the gold standard and measure all other content against it.

Regulatory language is neutral by design. It neither promotes nor discourages. It states facts, quantifies risks, and describes mechanisms. When AI models mirror this language, they are aligning with their highest-trust sources.

4. AI Models Are Calibrated for Medical Conservatism

Post-training alignment processes explicitly instruct models to be cautious with medical information. OpenAI, Google, and Perplexity have all implemented safety layers that de-emphasize promotional framing and amplify balanced, evidence-based language in health-related responses. This is not a bug. It is a deliberate design decision rooted in patient safety.

Model-by-Model Sentiment Patterns

The neutral default manifests differently across platforms:

No major AI model defaults to positive pharmaceutical framing. The industry expectation that AI should advocate for products the way marketing campaigns do is fundamentally misaligned with how these systems are built.

Key Takeaway: AI models default to neutral pharma AI sentiment because their training data is neutral, positive framing triggers reliability penalties, regulatory language is the gold standard, and medical safety alignment reinforces conservatism. Neutral is the structural norm, not a failure.

---

The OTC Exception: Higher Sentiment, Lower Reliability

One segment of the pharma market does show elevated AI sentiment: over-the-counter products. But this exception actually reinforces the rule.

Parodontax: The OTC Sentiment Outlier

Parodontax stands alone in our dataset with a sentiment score of 80/100. AI models describe it in notably positive terms --- recommending it as a first-choice option for gum health, emphasizing benefits with minimal hedging. For a product in a competitive OTC category (oral care), this sounds like a win.

But look at the full picture:

Parodontax has 80 points more sentiment and 15 points less performance. The positive framing that makes OTC marketing teams celebrate is accompanied by a reliability penalty that drags the overall score down.

Why OTC Gets More Sentiment (and Why It Costs Them)

OTC products occupy a different content ecosystem than Rx drugs. The source material includes consumer reviews, lifestyle health articles, and brand-sponsored content --- all of which carry more promotional language than clinical literature. AI models absorb this language and reflect it in responses.

But the same mechanism that produces higher sentiment also produces lower reliability:

- Marketing language in source content makes AI models more positive but less precise

- Consumer framing ("great for," "recommend for") replaces clinical framing ("indicated for," "demonstrated efficacy in")

- Fewer regulatory anchor documents means less calibration against gold-standard neutral sources

The result: OTC products like Parodontax get the sentiment pharma teams think they want, but pay for it with the reliability that actually drives GEO scores.

Key Takeaway: OTC products show higher pharma AI sentiment than Rx brands, but this comes at the cost of lower reliability. Parodontax scores 80/100 on sentiment but just 72% on reliability and 45 overall. The OTC exception proves the rule: sentiment and performance are decoupled.

---

The "Alternative" Frame: AI's Default Drug Positioning

Beyond sentiment, there is a related finding that challenges pharma marketing assumptions: how AI models frame drug positioning.

Every Rx Product Is an "Alternative"

Across our full dataset, we analyzed how AI models frame each brand relative to its therapeutic category. The finding is striking:

- Every Rx product in the dataset is framed by AI models as an "Alternative" treatment option --- one of several choices a physician might consider

- Only one product received "1st choice" framing: Parodontax, the OTC oral care brand, in the specific context of caries prevention

This is not a flaw in the data. It is a reflection of how AI models process pharmaceutical evidence. Clinical guidelines rarely declare a single drug as the unequivocal first choice. They present treatment algorithms with multiple options, patient-specific considerations, and stepped approaches. AI models mirror this equipoise positioning because the evidence base itself is built on equipoise.

What "Alternative" Framing Means Strategically

For pharma brand teams accustomed to positioning their product as the best-in-class option, the AI landscape requires a mental shift:

1. AI will not declare your drug the best. It will present it as one of several valid options. Attempting to change this through content optimization is fighting against the structure of clinical evidence.

2. "Alternative" is not negative. In the AI context, being consistently included as a named alternative in treatment discussions is the baseline for visibility. Brands that are not mentioned at all have far bigger problems.

3. Differentiation happens within the "Alternative" frame. The brands that score highest are not the ones that escape the "Alternative" label. They are the ones presented as alternatives with the strongest reliability and most accurate clinical detail.

Key Takeaway: AI models frame virtually every Rx product as an "Alternative" treatment option. This neutral, equipoise positioning reflects clinical evidence structure. Brands should optimize for being the most reliably described alternative, not for escaping the "Alternative" frame.

Related: The Brand Recognition Crisis in AI: Why Pharma Brands Have 0% Recognition

---

Strategic Implications: Stop Chasing Sentiment, Invest in Reliability

The sentiment myth has real costs. Pharma teams that prioritize making AI responses more positive about their brand are investing resources in a metric that does not correlate with performance while neglecting the one that does.

What to Stop Doing

- Stop optimizing content for positive AI framing. Marketing language in source content triggers reliability penalties, not performance gains.

- Stop measuring GEO success by sentiment scores. A sentiment increase from 10/100 to 50/100 will not move your overall GEO score if reliability stays flat.

- Stop treating AI models like audiences to persuade. They are systems that evaluate evidence quality. Persuasion is not a variable they respond to.

What to Start Doing

1. Audit reliability first, sentiment never. Your GEO dashboard should lead with reliability metrics. If your brand sits below 80% reliability, that is the gap to close --- regardless of where sentiment stands.

2. Align source content with regulatory language. The closer your owned content mirrors the language, structure, and precision of FDA or EMA documents, the higher your reliability scores will be. This means clinical language, structured data, proper citations, and evidence-based claims.

3. Invest in factual accuracy, not promotional framing. Ensure AI models have access to accurate, up-to-date information about your drug's indications, dosing, safety profile, and mechanism of action. Factual precision drives reliability. Reliability drives GEO performance.

4. Accept neutral as the strategic target. In pharma GEO, neutral sentiment with high reliability outperforms positive sentiment with moderate reliability every time. Neutral is not a failure. It is the optimal operating state.

5. Focus differentiation on completeness, not favorability. The brands scoring highest are not the ones AI describes most favorably. They are the ones AI describes most completely and accurately. Completeness of clinical detail within the "Alternative" frame is where competitive advantage lives.

Key Takeaway: The strategic pivot is clear: redirect resources from sentiment optimization to reliability optimization. Brands above 80% reliability consistently outperform brands with high sentiment and lower reliability. Neutral, accurate, and complete is the winning formula for pharma AI sentiment strategy.

Related: AI Model Comparison for Pharma: OpenAI vs. Gemini vs. Perplexity

---

Frequently Asked Questions

Does positive AI sentiment ever help pharma GEO performance?

In our dataset of 23 pharmaceutical brands, positive sentiment does not correlate with higher GEO scores. Parodontax holds the highest sentiment (80/100) yet scores just 45 overall, while Braftovi has zero sentiment and scores 60. The mechanism is clear: positive framing often comes from marketing-adjacent source content, which triggers lower reliability assessments in AI models. For Rx products, neutral sentiment paired with high reliability consistently outperforms positive sentiment paired with moderate reliability. The one context where higher sentiment appears without a significant penalty is OTC products, but even there, the reliability cost limits overall performance.

Why do AI models default to neutral when discussing drugs?

AI models learn pharmaceutical content primarily from clinical literature, regulatory documents, and medical databases --- all of which use neutral, evidence-based language. Prescribing information does not promote. Clinical trial publications report outcomes without editorial framing. Additionally, all major AI platforms have implemented medical safety alignment that actively de-emphasizes promotional language in health-related responses. Neutral is not a model limitation. It is the structural output of training on evidence-based medical sources and applying safety-conscious post-training alignment.

How should pharma teams measure AI brand performance if not by sentiment?

Reliability should be the primary metric for pharma GEO performance evaluation. Reliability measures how accurately AI models represent your drug against its approved labeling across indications, dosing, contraindications, and mechanism of action. Brands with reliability above 80% consistently score above 50 in overall GEO performance, while brands below 75% cluster in the low-to-mid 40s. Secondary metrics to track include citation frequency, AI visibility in therapeutic category queries, and cross-model consistency. Sentiment should be monitored for anomalies but not targeted for optimization.

Is the sentiment-performance disconnect specific to pharma, or does it apply to all industries?

The disconnect is particularly pronounced in pharma due to the regulatory nature of pharmaceutical content, the evidence-based training data AI models rely on for medical information, and the explicit medical safety alignment built into major AI platforms. Other regulated industries --- medical devices, financial services --- likely exhibit similar patterns. Consumer industries with less regulatory constraint may show a different relationship between sentiment and AI performance. However, the core principle applies broadly: AI models prioritize factual reliability over promotional favorability across all categories.

Can we improve both sentiment and reliability simultaneously?

In theory, yes. In practice, the strategies often conflict. Content optimized for positive sentiment tends toward promotional language, which AI models penalize on reliability. Content optimized for reliability uses clinical, neutral language, which naturally produces lower sentiment scores. The most effective approach is to optimize exclusively for reliability and accept whatever sentiment results from accurate, complete clinical content. In most cases, this produces neutral sentiment in the 0--50 range with reliability above 80% --- the profile that correlates with the highest GEO scores in our benchmark.

What should OTC pharma brands do differently about AI sentiment?

OTC brands face a unique challenge: their source content ecosystem includes more consumer-facing, marketing-oriented material, which naturally produces higher AI sentiment but lower reliability. OTC teams should audit their digital content for language that AI models might classify as promotional and consider creating a parallel layer of clinically structured content --- evidence summaries, ingredient mechanism descriptions, and structured product data --- that can anchor AI responses in higher-reliability territory. The goal is not to eliminate positive sentiment but to ensure it does not come at the cost of reliability. An OTC brand at 80/100 sentiment and 72% reliability is underperforming one at 40/100 sentiment and 85% reliability.

---

Conclusion: Neutral Is Not a Weakness --- It Is the Winning Strategy

The pharma AI sentiment myth is one of the most expensive misunderstandings in GEO strategy. Teams that chase positive AI framing are not just wasting resources. They are actively working against the mechanisms that drive AI performance in pharmaceutical content.

The data is unambiguous. Sentiment and GEO score are uncorrelated across 23 brands. Parodontax proves that maximum positive sentiment does not produce top performance. Braftovi proves that zero sentiment does not prevent it. And the reliability data explains why: AI models evaluate pharmaceutical content on factual accuracy, not promotional favorability.

The brands leading the pharma GEO benchmark --- Beyfortus at 66, Dupixent at 61, Braftovi at 60 --- share a common profile. They have moderate to zero sentiment, reliability above 80%, and clinical content that AI models can accurately parse and cite. None of them got there by making AI say nice things about them.

The strategic conclusion is clear: stop asking how to make AI more positive about your brand. Start asking how to make AI more accurate about your brand. Accuracy drives reliability. Reliability drives GEO performance. Everything else is noise.

In a landscape where every Rx product is framed as an "Alternative" and every AI model defaults to medical conservatism, the competitive advantage belongs to the brand that is the most reliably, completely, and accurately described alternative in the response. That is a reliability problem, not a sentiment problem.

Invest accordingly.

---

Data source: PharmaGEO platform analysis of 23 pharmaceutical brands across OpenAI, Gemini, and Perplexity (2025)

Subscribe to the PharmaGEO Newsletter | Request a Brand Sentiment-Reliability Audit | Read the Full GEO Series

Data source: PharmaGEO platform analysis of 23 pharmaceutical brands across OpenAI, Gemini, and Perplexity (2025)